Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 600 results for diabetes

  1. Weight management: overweight register (IND237)

    This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 23 kg/m2 or more (or 25 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM221

  2. When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    NG19/2 Question When and with what criteria should people with diabetes be referred to the foot protection service or the...

  3. When and with what criteria should people with diabetes be referred to the foot protection service or the multidisciplinary foot care service?

    NG19/2 Question When and with what criteria should people with diabetes be referred to the foot protection service or the...

  4. Heart failure: beta blockers (IND194)

    This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with a beta-blocker licensed for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM173

  5. Inducing labour (NG207)

    This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.

  6. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

  7. Vamorolone for treating Duchenne muscular dystrophy [ID4024]

    In development [GID-TA11135] Expected publication date: TBC

  8. How effective and cost effective are interventions which use either a 'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower socioeconomic groups?

    'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower...

  9. Bipolar, schizophrenia and other psychoses: target organ damage (IND86)

    This indicator covers the percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM21

  10. Kidney conditions: CKD urine albumin:creatinine ratio (IND144)

    This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109

  11. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

  12. Dementia: target organ damage (all patients) (IND118)

    This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72

  13. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

  14. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.